Norah L. Henry, MD, anticipates an array of impactful presentations at the upcoming San Antonio Breast Cancer Symposium, particularly on new treatments for metastatic and early-stage breast cancer. Highlights include updates from the DESTINY-Breast06 and EMBER-3 trials on promising drugs for HER2-low and ER-positive metastatic breast cancer, as well as findings from the PADMA trial comparing endocrine therapy vs chemotherapy.
The symposium will also showcase novel early-stage therapies, biomarker studies, and insights into surgery and radiation omission for certain patients. Dr Henry looks forward to discussing these clinically relevant findings with colleagues.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Breast Cancer Advances at SABCS 2024 - Medscape - Dec 02, 2024.
Comments